Phase II Study of the Enzyme Inhibitor NTBC for Tyrosinemia Type I
Assess whether 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) at 0.6 mg/kg per day prevents liver failure in at least 1 patient with tyrosinemia type I.
|Study Design:||Primary Purpose: Treatment|
|Study Start Date:||November 1994|
PROTOCOL OUTLINE: Only 2 patients with tyrosinemia type I are known to this research team; others will be treated if found and if clinical conditions permit.
The enzyme inhibitor 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) is administered orally, in 2 divided doses daily with meals.
Patients will be followed closely for side effects attributable to NTBC.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00004333
|Study Chair:||Jess G. Thoene||University of Michigan|